Serum ghrelin concentrations in patients receiving olanzapine or risperidone |
| |
Authors: | Takashi Togo Koichi Hasegawa Satoshi Miura Hideki Hosojima Katsuo Kojima Mika Shoji Akihiko Kase Hirotake Uchikado Eizo Iseki Kenji Kosaka |
| |
Affiliation: | (1) Department of Psychiatry, Yokohama Maioka Hospital, Maioka-cho 3482, Totsuka-ku, 244-0813 Yokohama, Japan;(2) Department of Psychiatry, Yokohama City University School of Medicine, Yokohama, Japan;(3) Radioisotope Research Center, Yokohama City University School of Medicine, Yokohama, Japan |
| |
Abstract: | Rationale Although enhanced appetite and weight gain are potential side effects of treatment with antipsychotic agents, particularly olanzapine and clozapine, the mechanism is poorly understood.Objectives To test the hypothesis that ghrelin, a gastrointestinal hormone that enhances appetite, is involved in increased food intake and weight gain during treatment with antipsychotics.Methods Serum ghrelin concentrations were investigated in schizophrenic patients receiving olanzapine or risperidone, and in healthy volunteers.Results Serum ghrelin concentrations did not increase, but rather decreased, in patients treated with olanzapine or risperidone in comparison with healthy volunteers. No significant difference was found in serum ghrelin concentration between patients treated with olanzapine and risperidone.Conclusions Our results indicate that ghrelin is not a direct cause of increased food intake and weight gain during treatment with olanzapine or risperidone, whereas ghrelin is associated with metabolic change in patients receiving these agents. |
| |
Keywords: | Ghrelin Olanzapine Risperidone Appetite Weight gain |
本文献已被 PubMed SpringerLink 等数据库收录! |
|